Results 91 to 100 of about 8,209 (210)
Treatment of disseminated granuloma annulare with pulse therapy upadacitinib [PDF]
Granuloma annulare (GA) is an idiopathic inflammatory skin condition with a chronic and unpredictable course. Although localized GA is usually cleared with topical or systemic corticosteroids, generalized GA is often difficult to treat owing to the lack ...
Bialick, Mallorie +3 more
core +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.Forty‐three HS specialists from 22 European countries reported adherence to HS guidelines and use of antibiotics before biologics despite limited efficacy and rapid relapse (49% within 1–3 months). Seventy‐nine per cent supported short‐term biologics for severe Hurley I disease.
Georgios Nikolakis +41 more
wiley +1 more source
Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study [PDF]
This study evaluates upadacitinib (UPA) effectiveness and drug retention rate (DRR) in patients with rheumatoid arthritis (RA). Multicentre prospective observational study. Consecutive patients with RA receiving UPA were evaluated at 0, 3, 6, 12, 18, and
Baldi, Caterina +17 more
core +1 more source
Therapeutic advances in pruritus as a model of personalized medicine
Journal of the European Academy of Dermatology and Venereology, EarlyView.Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung +2 more
wiley +1 more source
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
Journal of the European Academy of Dermatology and Venereology, EarlyView.The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick +13 more
wiley +1 more source
RMD OpenIntroduction Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain.Methods Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed ...
Bruno Fautrel +10 more
doaj +1 more source
JANUS KINASE ENZYME (JAK) INHIBITORS AND RHEUMATOID ARTHRITIS: A REVIEW OF THE LITERATURE [PDF]
, 2019 Cytokines play an essential role in normal cell growth and the regulation of immune function. The emergence of Janus Kinase Enzyme inhibitors promises the start of a revolution in the treatment of several chronic diseases.
ASKARI, AYMAN +3 more
core +1 more source
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis [PDF]
Background Prurigo nodularis (PN) is a debilitating skin condition. When inadequate disease control is achieved or other systemic therapies are contraindicated, Janus kinase inhibitors (JAKis) may be considered, although real-world evidence remains ...
Alessandra Narcisi +46 more
core +1 more source